Investor Alert

London Markets Open in:

Market Pulse Archives

July 13, 2020, 6:41 a.m. EDT

ACell sets IPO terms, could be valued at up to $362.8 million

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Renaissance IPO ETF (IPO)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

ACell Inc. set terms of its initial public offering, in which the Maryland-based regenerative medicine company focused on severe wounds treatment looks to raise up to $80 million and be valued at up to $362.8 million. The company is selling 5 million shares in the IPO, which is expected to price between $14 and $16 a share. There will be 22.68 million shares outstanding after the IPO. UBS, Barclays, RBC Capital Market and SunTrust Robinson Humphrey are the lead underwriters. The recorded a net loss of $2.7 million on revenue of $23.68 million over the three months ended March 31, after net income of $66,000 on revenue of $24.15 million in the same period a year ago. The company is looking to go public at a time that the Renaissance IPO ETF /zigman2/quotes/207665280/composite IPO -3.87% has soared 61.7% over the past three months while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.06% has advanced 15.3%.

US : U.S.: NYSE Arca
$ 44.48
-1.79 -3.87%
Volume: 103,994
Aug. 7, 2020 3:59p
+2.12 +0.06%
Volume: 2.28B
Aug. 7, 2020 5:10p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.